Price Target https://www.benzinga.com/views/taxonomy/term/72 en Peloton Analysts Bullish After Earnings Beat: 'Recalls Not As Bad As Feared' https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21017432/peloton-analysts-bullish-after-earnings-beat-recalls-not-as-bad-as-feared <p><strong>Peloton Interactive Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pton#NASDAQ">PTON</a>) shares rebounded by 2.6% on Friday after the company reported impressive fiscal third-quarter sales growth and assured investors it&rsquo;s working quickly to resolve safety issues with its treadmills.</p> <p>For the fiscal third quarter, Peloton reported a 3-cent EPS loss, beating the 12-cent loss analysts had expected. Peloton also reported $1.26 billion in revenue, ahead of the $1.1 billion consensus analyst estimate. Revenue was up 141% from a year ago.</p> <p><em>Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21013325/square-reports-q1-earnings-what-do-analysts-think">Square Reports Q1 Earnings: What Do Analysts Think?</a> </em></p> <p>Peloton reported $1.02 billion in connected fitness revenue, up 140%. The company also reported $239.4 million in subscription revenue in the quarter, up 144%.</p> <p>Peloton&rsquo;s earnings report comes the same week the company issued&nbsp;a recall of all of its treadmill products that the company said will have a $165 million impact on its fiscal fourth-quarter sales. Peloton is now guiding for $915 million in fourth-quarter revenue.</p> <p><strong>Near-Term Headwinds:</strong> Bank of America analyst Justin Post said Peloton&rsquo;s ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21017432/peloton-analysts-bullish-after-earnings-beat-recalls-not-as-bad-as-feared alt=Peloton Analysts Bullish After Earnings Beat: &#039;Recalls Not As Bad As Feared&#039;>Full story available on Benzinga.com</a></p> Aaron Kessler Analyst Color Bank of America Bernie McTernan Dana Telsey Edward Yruma Justin Post KeyBanc Needham News PTON Raymond James Telsey Advisory Group Price Target Analyst Ratings PTON News Analyst Color Price Target Analyst Ratings Benzinga Fri, 07 May 2021 21:20:36 +0000 Wayne Duggan 21017432 at https://www.benzinga.com Tilray Stock Is Getting Squeezed Between 2 Key Levels https://www.benzinga.com/markets/cannabis/21/05/21015502/tilray-stock-is-getting-squeezed-between-2-key-levels <p><strong>Tilray Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlry#NASDAQ">TLRY</a>) shares were trading higher Friday&nbsp;after a Jefferies analyst double upgraded&nbsp;the stock.</p> <p>The stock was double upgraded from Underperform to Buy and the price target was raised from $4.77 to $23.</p> <p>Tilray recently closed a merger with <strong>Aphria Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apha#NASDAQ">APHA</a>).</p> <p><a href="https://www.benzinga.com/markets/cannabis/21/05/21012905/why-tilrays-stock-is-trading-higher-today">Click here</a> to read more about why Tilray is moving.&nbsp;</p> <p>Tilray was up 14.7% at $16.23 ahead of the market close Friday.&nbsp;</p> <p><img alt="tlrydaily5-7-21.png" src="https://cdn.benzinga.com/files/u285825/tlrydaily5-7-21.png" style="height:400px; width:640px" /></p> <h3>Tilray Daily Chart Analysis</h3> <ul> <li>The stock is getting squeezed between a previous support and a potential resistance line. The stock may see a strong move in the upcoming weeks.</li> <li>The stock is trading below the 50-day moving average (green)&nbsp;and above the 200-day moving average (blue), indicating the stock is likely trading in a period of consolidation.</li> <li>The ...</li></ul><p><a href=https://www.benzinga.com/markets/cannabis/21/05/21015502/tilray-stock-is-getting-squeezed-between-2-key-levels alt=Tilray Stock Is Getting Squeezed Between 2 Key Levels>Full story available on Benzinga.com</a></p> APHA Cannabis Long Ideas News TLRY Short Ideas Upgrades Price Target Technicals Markets Analyst Ratings Movers Trading Ideas TLRY US88688T1007 APHA Long Ideas News Cannabis Short Ideas Upgrades Price Target Technicals Markets Analyst Ratings Movers Trading Ideas Benzinga Fri, 07 May 2021 20:06:16 +0000 Tyler Bundy 21015502 at https://www.benzinga.com What Is Roku's Secret Weapon? Analysts React To Q1 Earnings, Tough Comps Ahead https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21014356/what-is-rokus-secret-weapon-analysts-react-to-q1-earnings-tough-comps-ahead <p><strong>Roku Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roku#NASDAQ">ROKU</a>) shares are trading higher&nbsp;after beating revenue and eps estimates for the first quarter. Analysts are out with reactions to the first quarter and thoughts on difficult comps ahead.</p> <p><strong>The Roku Analysts: </strong>Morgan Stanley analyst Benjamin Swinburne reiterates an Underweight rating on Roku&nbsp;and lowers the price target from $300 to $275.</p> <p>Rosenblatt analyst Mark Zgutowicz reiterates a Buy rating and has a $560 price target.</p> <p>Needham analyst Laura Martin reiterates a Buy rating and has a $550 price target.</p> <p>KeyBanc analyst Justin Patterson reiterates an Overweight rating and lowers the price target from $518 to $460.</p> <p><em>Related Link: <a href="https://www.benzinga.com/news/earnings/21/05/21001331/roku-shares-climb-on-q1-revenue-eps-beat-strong-guidance">Roku Shares Climb On Q1 Revenue, EPS Beat, Strong Guidance</a></em></p> <p><strong>Q1 Takeaways: </strong>Swinburne called Roku media&rsquo;s favorite streaming partner saying the company continues to impress and provide more value for its partners.</p> <p>&ldquo;This was particularly clear in stronger than expected 1Q revenue growth and margins,&rdquo; Swinburne said.</p> <p>The SVOD wars are heating up and Roku looks to be the continued winner, Zgutowicz ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21014356/what-is-rokus-secret-weapon-analysts-react-to-q1-earnings-tough-comps-ahead alt=What Is Roku&#039;s Secret Weapon? Analysts React To Q1 Earnings, Tough Comps Ahead>Full story available on Benzinga.com</a></p> Analyst Color Benjamin Swinburne Earnings Justin Patterson KeyBanc Laura Martin Mark Zgutowiz Morgan Stanley Needham News NFLX ROKU Rosenblatt streaming stocks The Roku Channel Price Target Reiteration Top Stories Analyst Ratings Trading Ideas NFLX US64110L1061 ROKU News Analyst Color Earnings Price Target Reiteration Top Stories Analyst Ratings Trading Ideas Benzinga Fri, 07 May 2021 19:40:19 +0000 Chris Katje 21014356 at https://www.benzinga.com Microchip Technology Beats On Q4 Earnings Stemming From Strong Demand, Raises Quarterly Dividend https://www.benzinga.com/news/earnings/21/05/21012894/microchip-technology-beats-on-q4-earnings-stemming-from-strong-demand-raises-quarterly-dividend <ul> <li><strong>Microchip Technology Inc</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/mchp#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">MCHP</a>)&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/05/g21000411/microchip-technology-announces-record-financial-results-for-fourth-quarter-and-fiscal-year-2021" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">reported fourth-quarter</a>&nbsp;FY21 net sales growth of $10.6% year-on-year to $1.467 billion, beating the analyst consensus of $1.46 billion.</li> <li>Non-GAAP gross margin expanded 210 basis points to 64.1%, and Non-GAAP operating margin expanded 410 basis points to 40.7%.</li> <li>The non-GAAP operating income rose 22.9% Y/Y to $596.9 million.</li> <li>Non-GAAP net income rose 38.9% Y/Y to $521.4 million, with the adjusted EPS of $1.85 beating the analyst consensus of $1.75.</li> <li>The company generated $449.2 million in operating cash flow and held $282 million in cash and equivalents.</li> <li>The ...</li></ul><p><a href=https://www.benzinga.com/news/earnings/21/05/21012894/microchip-technology-beats-on-q4-earnings-stemming-from-strong-demand-raises-quarterly-dividend alt=Microchip Technology Beats On Q4 Earnings Stemming From Strong Demand, Raises Quarterly Dividend>Full story available on Benzinga.com</a></p> Briefs Earnings MCHP News Guidance Dividends Price Target Analyst Ratings Tech Media MCHP US5950171042 News Earnings Guidance Dividends Price Target Analyst Ratings Tech Media Benzinga Fri, 07 May 2021 18:34:06 +0000 Anusuya Lahiri 21012894 at https://www.benzinga.com 2 Beyond Meat Analysts Offer Split Opinions About Q1 Earnings https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21014504/2-beyond-meat-analysts-offer-split-opinions-about-q1-earnings <p>The plant-based meat provider <strong>Beyond Meat, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bynd#NASDAQ">BYND</a>) served up a dismal Q1 earnings report yesterday, with a net loss was $27.3 million compared to net income of $1.8 million one year earlier and a gross profit of $32.7 million versus a $37.7 million figure from the previous year. Adjusted EBITDA was a loss of $10.8 million, or -10% of net revenues, compared to Adjusted EBITDA of $13.9 million, or 14.3% of net revenues, in Q1 2020.</p> <p>The company&rsquo;s earnings were studied by a pair of analysts who offered very different conclusions based on the new data.</p> <p><strong>Stephen&rsquo;s Half-Full Glass:</strong> For Stephens &amp; Co. analyst Mark Connelly, Beyond Meat&rsquo;s Q1 results were good enough to warrant an Overweight rating and a $190 price target.</p> <p>Connelly theorized that the company&rsquo;s quarterly numbers were the result of the costs related to investing in research and development, staffing and the expansion of its manufacturing facilities in Europe and Asia.</p> <p>He observed that driving revenues in food service was difficult due to lower capacity or continued closures &mdash;&nbsp;especially in Europe &mdash;&nbsp;and he also seemed unconcerned about additional losses for the remainder of the year.</p> <p>&ldquo;Turning a profit isn&#39;t the priority for 2021, and neither is food ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21014504/2-beyond-meat-analysts-offer-split-opinions-about-q1-earnings alt=2 Beyond Meat Analysts Offer Split Opinions About Q1 Earnings>Full story available on Benzinga.com</a></p> Analyst Color btig BYND food service industry MCD News Q1 earnings Stephens YUM Price Target Restaurants Analyst Ratings Trading Ideas General MCD US5801351017 YUM US9884981013 BYND News Analyst Color Price Target Restaurants Analyst Ratings Trading Ideas General Benzinga Fri, 07 May 2021 16:47:13 +0000 Phil Hall 21014504 at https://www.benzinga.com Square Reports Q1 Earnings: What Do Analysts Think? https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21013325/square-reports-q1-earnings-what-do-analysts-think <p><strong>Square Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sq#NASDAQ">SQ</a>) shares traded higher by 6% on Friday morning after the company reported a <strong>Bitcoin</strong> (CRYPTO: BTC)-fueled surge in first-quarter revenue.</p> <p>For the first quarter, Square reported 41 cents in EPS on revenue of $5.06 billion. Both numbers beat consensus analyst estimates of 16 cents and $3.36 billion, respectively. Revenue was up 266% from a year ago.</p> <p><em>Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/05/20991632/uber-analysts-bullish-after-q1-report-mobilitys-recovery-continues-to-progress">Uber Analysts Bullish After Q1 Report: &#39;Mobility&#39;s Recovery Continues To Progress&#39;</a> </em></p> <p>Gross profit from the company&rsquo;s Cash App was up $171&nbsp;to $495 million.</p> <p>Square also reported $3.5 billion in Bitcoin revenue and $75 million in Bitcoin gross profit in the quarter. Square said it lost $20 million on the $170 million worth of Bitcoin it purchased in February, as of March 31. Square said it now holds roughly $472 million in Bitcoin.</p> <p><strong>Multiple Growth Drivers:</strong> BTIG analyst Mark Palmer said Square&rsquo;s report demonstrates ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21013325/square-reports-q1-earnings-what-do-analysts-think alt=Square Reports Q1 Earnings: What Do Analysts Think?>Full story available on Benzinga.com</a></p> Analyst Color Bank of America btig Earnings Fintech Jason Kupferberg Josh Beck KeyBanc Mark Palmer Mayank Tandon Needham News Rosenblatt Securities Sean Horgan SPY SQ Price Target Analyst Ratings SPY US78462F1030 SQ News Analyst Color Earnings Fintech Price Target Analyst Ratings Benzinga Fri, 07 May 2021 16:14:29 +0000 Wayne Duggan 21013325 at https://www.benzinga.com Jefferies Upgrades Tilray On EU, US Prospects https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21013691/jefferies-upgrades-tilray-on-eu-us-prospects <p>The merger between <strong>Tilray Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlry#NASDAQ">TLRY</a>) and Aphria was a &ldquo;perfect match&rdquo; and the entity could generate pro-forma sales growth of 33% between fiscal 2021 and 2024, according to Jefferies.</p> <p><strong>The Tilray Analyst: </strong>Owen Bennett upgraded the rating for Tilray from Underperform to Buy, while raising the price target from $4.77 to $23.</p> <p><strong>The Tilray Thesis:</strong> The company has a stronger sales and profit growth profile than its closest Canadian peers, <strong>Canopy Growth Corp</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) and <strong>Cronos Group </strong>(NASDAQ: <a class="ticker" ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21013691/jefferies-upgrades-tilray-on-eu-us-prospects alt=Jefferies Upgrades Tilray On EU, US Prospects>Full story available on Benzinga.com</a></p> Analyst Color Cannabis cannabis industry CGC CRON Jefferies Owen Bennett TLRY Upgrades Price Target Markets Analyst Ratings CGC CRON TLRY US88688T1007 Analyst Color Cannabis Upgrades Price Target Markets Analyst Ratings Benzinga Fri, 07 May 2021 15:35:15 +0000 Priya Nigam 21013691 at https://www.benzinga.com APPN Stock Takes A Hit As Guidance Fails To Impress Wall Street https://www.benzinga.com/news/earnings/21/05/21011835/appn-stock-takes-a-hit-as-guidance-fails-to-impress-wall-street <ul> <li><strong>Appian Corp</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/appn#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">APPN</a>)&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/05/g20999426/appian-announces-first-quarter-2021-financial-results" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">reported first-quarter</a>&nbsp;FY21 revenue growth of 13% year-on-year to $88.9 million, beating the analyst consensus of $82.7 million.</li> <li>Cloud subscription revenue rose 38% Y/Y to $39.1 million, Total subscription revenue increased 26% Y/Y to $63.8 million, while Professional services revenue declined 12% Y/Y to $25.1 million.</li> <li>Non-GAAP operating loss reduced 82.4% Y/Y to $0.9 million.</li> <li>Non-GAAP net loss reduced 51.2% Y/Y to $4 million with an adjusted EPS loss of ($0.06), beating the analyst consensus of ($0.14) loss.</li> <li>Adjusted EBITDA was ...</li></ul><p><a href=https://www.benzinga.com/news/earnings/21/05/21011835/appn-stock-takes-a-hit-as-guidance-fails-to-impress-wall-street alt=APPN Stock Takes A Hit As Guidance Fails To Impress Wall Street>Full story available on Benzinga.com</a></p> APPN Briefs Earnings News Guidance Price Target Analyst Ratings Tech Media APPN News Earnings Guidance Price Target Analyst Ratings Tech Media Benzinga Fri, 07 May 2021 15:16:57 +0000 Anusuya Lahiri 21011835 at https://www.benzinga.com Analysts React To FDA AdCom Vote On ChemoCentryx's Avacopan, Stock Plunges https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21011933/analysts-react-to-fda-adcom-vote-on-chemocentryxs-avacopan-stock-plunges <ul> <li>Yesterday, the FDA&rsquo;s Arthritis Advisory Committee panelists went through cloudy data while complaining about the design of the Phase 3 trial for&nbsp;<strong>ChemoCentryx Inc&rsquo;s</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/ccxi#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">CCXI</a>) avacopan. After going over time, they&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/21/05/21008128/adcomm-split-on-fda-approval-for-chemocentryxs-vasculitis-candidate" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">ended up without consensus</a>.</li> <li>This orphan drug has July 7 as its PDUFA date.</li> <li>What do analysts have to say after the AdCom splits slightly in favor of FDA approving this rare disease drug:</li> <li>Raymond James analyst Steven Seedhouse, on a reduced conviction in avacopan approval, downgraded the stock to Outperform from Strong Buy with the price target more than halved to $51 from $120. <ul> <li class="ql-indent-1">However, if approved, Seedhouse still thinks avacopan is a blockbuster drug and will ...</li></ul></li></ul><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21011933/analysts-react-to-fda-adcom-vote-on-chemocentryxs-avacopan-stock-plunges alt=Analysts React To FDA AdCom Vote On ChemoCentryx&#039;s Avacopan, Stock Plunges>Full story available on Benzinga.com</a></p> Analyst Color Arthritis Biotech Briefs CCXI News Downgrades Health Care Price Target Small Cap FDA Analyst Ratings General CCXI News Analyst Color Biotech Downgrades Health Care Price Target Small Cap FDA Analyst Ratings General Benzinga Fri, 07 May 2021 14:17:16 +0000 Vandana Singh 21011933 at https://www.benzinga.com 10 Biggest Price Target Changes For Friday https://www.benzinga.com/analyst-ratings/price-target/21/05/21011040/10-biggest-price-target-changes-for-friday <ul> <li>Stifel boosted <strong> Wayfair Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/w#NYSE">W</a>) price target from $200 to $280. Wayfair shares rose 1.7% to $290.91 in pre-market trading.</li> <li>RBC Capital raised <strong> ViacomCBS Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/viac#NASDAQ">VIAC</a>) price target from $26 to $52. ViacomCBS shares rose 1.7% to $38.78 in pre-market trading.</li> <li>JP Morgan lifted the price target on <strong> Albemarle Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alb#NYSE">ALB</a>) from $125 to $152. Albemarle shares rose 0.5% to $153.61 in pre-market trading.</li> <li>Citigroup boosted the price target on <strong> Tupperware Brands Corporation</strong> ...</li></ul><p><a href=https://www.benzinga.com/analyst-ratings/price-target/21/05/21011040/10-biggest-price-target-changes-for-friday alt=10 Biggest Price Target Changes For Friday>Full story available on Benzinga.com</a></p> ALB APD APPN CCXI Price Target Changes PZZA ROKU TUP VIAC W XRAY Price Target Small Cap Pre-Market Outlook Analyst Ratings PZZA US6988131024 XRAY US2490301072 ALB US0126531013 APD US0091581068 TUP US8998961044 CCXI W VIAC APPN ROKU Price Target Small Cap Pre-Market Outlook Analyst Ratings Benzinga Fri, 07 May 2021 12:47:55 +0000 Lisa Levin 21011040 at https://www.benzinga.com What 3 Analysts Think About Etsy's Future Growth After Q1 Earnings Report https://www.benzinga.com/analyst-ratings/analyst-color/21/05/20994636/what-3-analysts-think-about-etsys-future-growth-after-q1-earnings-report <p>Analysts are reacting to the first-quarter earnings report from <strong>Etsy Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etsy#NASDAQ">ETSY</a>) and the second-quarter guidance for the e-commerce company.</p> <p><strong>The Etsy Analysts:</strong> Roth Capital analyst Darren Aftahi has a Buy rating&nbsp;and a $245 price target.</p> <p>Morgan Stanley analyst Lauren Schenk has an Underweight rating and raises the price target from $123 to $135.</p> <p>KeyBanc analyst Edward Yruma has a Sector Weight rating and no price target on shares.</p> <p><strong>First Quarter Strength:</strong> Etsy&rsquo;s product assortment helped the company&rsquo;s gross merchandise sales in the <a href="https://www.benzinga.com/news/earnings/21/05/20975348/etsy-q1-earnings-insights">first quarter</a>. Habitual buyers represented 9% of active buyers in the first quarter, but represented 40% of GMS.</p> <p>GMS was up 132% year-over-year in the first quarter.</p> <p>There are many concerns over the decline in mask sales from Etsy as sales of the COVID-19 pandemic-related item have fallen. The ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/05/20994636/what-3-analysts-think-about-etsys-future-growth-after-q1-earnings-report alt=What 3 Analysts Think About Etsy&#039;s Future Growth After Q1 Earnings Report>Full story available on Benzinga.com</a></p> Analyst Color Darren Aftahi ecommerce Edward Yruma ETSY KeyBanc Lauren Schenk Morgan Stanley Roth Capital Price Target Reiteration Analyst Ratings Trading Ideas ETSY Analyst Color Price Target Reiteration Analyst Ratings Trading Ideas Benzinga Thu, 06 May 2021 21:59:19 +0000 Chris Katje 20994636 at https://www.benzinga.com Uber Analysts Bullish After Q1 Report: 'Mobility's Recovery Continues To Progress' https://www.benzinga.com/analyst-ratings/analyst-color/21/05/20991632/uber-analysts-bullish-after-q1-report-mobilitys-recovery-continues-to-progress <p><strong>Uber Technologies Inc</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uber#NYSE">UBER</a>) shares traded lower by 6.8% on Thursday morning after the company reported first-quarter revenue that fell short of Wall Street expectations.</p> <p>For the first quarter, Uber reported an adjusted EPS loss of 6 cents, beating consensus analyst estimates of a 54-cent loss. Uber also reported $2.9 billion in revenue, missing consensus estimates of $3.29 billion. Revenue was down 11% from a year ago.</p> <p><em>Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/05/20971782/line-of-sight-to-positive-ebitda-analysts-react-to-lyft-earnings">&#39;Line Of Sight To Positive EBITDA&#39;: Analysts React To Lyft Earnings</a> </em></p> <p>Uber reported $6.77 billion in Mobility gross bookings, down 38% from a year ago. It generated $12.46 billion in Delivery gross bookings, up 166% from last year.</p> <p>Uber&rsquo;s $108 million net loss in the quarter was a significant improvement from its $968 million net loss a year ago. However, the company&rsquo;s bottom line benefitted from a $1.6 billion gain from the sale of Uber&rsquo;s self-driving unit, and Uber&rsquo;s actual operating loss on the quarter was still more than $1.5 billion.</p> <p><strong>Regulatory Overhangs:</strong> Wedbush analyst Daniel Ives said Uber is showing signs of ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/05/20991632/uber-analysts-bullish-after-q1-report-mobilitys-recovery-continues-to-progress alt=Uber Analysts Bullish After Q1 Report: &#039;Mobility&#039;s Recovery Continues To Progress&#039;>Full story available on Benzinga.com</a></p> Aaron Kessler Analyst Color Bank of America Bernie McTernan Brian Nowak D.A. Davidson Daniel Ives delivery Earnings Justin Post Morgan Stanley Needham News Raymond James rideshare Tom White UBER Wedbush Price Target Analyst Ratings UBER News Analyst Color Earnings Price Target Analyst Ratings Benzinga Thu, 06 May 2021 20:32:32 +0000 Wayne Duggan 20991632 at https://www.benzinga.com Bring On The Olive Garden Breadsticks! Analyst Is Bullish For Darden Restaurants https://www.benzinga.com/analyst-ratings/analyst-color/21/05/20992125/bring-on-the-olive-garden-breadsticks-analyst-is-bullish-for-darden-restaurants <p>Despite industry-related input costs and labor headwinds, <strong>Darden Restaurants, Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dri#NYSE">DRI</a>) could generate above-consensus earnings in fiscal 2023, driven by Olive Garden sales, according to Cowen.</p> <p><strong>The Darden Restaurants Analyst:</strong> Andrew Charles upgraded the rating for Darden Restaurants from Market Perform to Outperform, while raising the price target from $137 to $164.</p> <p><strong>The Darden Restaurants Thesis: </strong>Olive Garden seems poised to grow its average unit volume from $5 million in 2019 to $6 million in fiscal 2023, Charles said in ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/05/20992125/bring-on-the-olive-garden-breadsticks-analyst-is-bullish-for-darden-restaurants alt=Bring On The Olive Garden Breadsticks! Analyst Is Bullish For Darden Restaurants>Full story available on Benzinga.com</a></p> Analyst Color Andrew Charles breadsticks Cowen DRI food Olive Garden Upgrades Price Target Restaurants Analyst Ratings General DRI US2371941053 Analyst Color Upgrades Price Target Restaurants Analyst Ratings General Benzinga Thu, 06 May 2021 20:08:11 +0000 Priya Nigam 20992125 at https://www.benzinga.com Global Blood Therapeutics Q1 Earnings Miss Estimates On Disappointing Sales For Its Sickle-Cell Disease Drug https://www.benzinga.com/general/biotech/21/05/20994871/global-blood-therapeutics-q1-earnings-miss-estimates-on-disappointing-sales-for-its-sickle-cell-d <ul> <li><strong>Global Blood Therapeutics Inc</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/gbt#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">GBT</a>)<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/05/g20974007/gbt-reports-first-quarter-2021-financial-results" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">&nbsp;reported a Q1 EPS loss</a>&nbsp;of ($1.21) wider than the anticipated loss estimate of $1.01.</li> <li>Q1 sales of $39.04 million well below the consensus of $43.00 million, all of which stemmed from sickle-cell disease drug, Oxbryta.</li> <li>Revenues increased 177% Y/Y, but on a sequential basis, sales decreased 5%, driven primarily by lower inventory levels and a higher gross-to-net adjustment, partially offset by patient demand.</li> <li>The company blamed the disappointing performance for Oxbryta on COVID-19. It said there were fewer interactions with healthcare providers and patients in the first quarter due to the increased number of cases of COVID-19 in the U.S. As a result, new prescriptions ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/05/20994871/global-blood-therapeutics-q1-earnings-miss-estimates-on-disappointing-sales-for-its-sickle-cell-d alt=Global Blood Therapeutics Q1 Earnings Miss Estimates On Disappointing Sales For Its Sickle-Cell Disease Drug>Full story available on Benzinga.com</a></p> Biotech Briefs Earnings GBT News Guidance Health Care Price Target Analyst Ratings General GBT News Earnings Biotech Guidance Health Care Price Target Analyst Ratings General Benzinga Thu, 06 May 2021 19:03:46 +0000 Vandana Singh 20994871 at https://www.benzinga.com Why Is Costco's Stock Trading Higher Today? https://www.benzinga.com/news/21/05/20994514/why-is-costcos-stock-trading-higher-today <p><strong>Costco Wholesale Corporation</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cost#NASDAQ">COST</a>) shares are trading higher after the company reported April sales results up from last year. The company reported $15.21 billion for the retail month of April, which is a 33.5% year-over-year increase.</p> <p>Telsey Advisory Group also maintained an Outperform rating on the stock and raises its price target from $390 to $395.</p> <p>Costco ...</p><p><a href=https://www.benzinga.com/news/21/05/20994514/why-is-costcos-stock-trading-higher-today alt=Why Is Costco&#039;s Stock Trading Higher Today?>Full story available on Benzinga.com</a></p> COST News why it's moving Price Target Analyst Ratings Movers Trading Ideas COST US22160K1051 News Price Target Analyst Ratings Movers Trading Ideas Benzinga Thu, 06 May 2021 16:40:48 +0000 Randy Elias 20994514 at https://www.benzinga.com